CXCR3 and neoplasm: Extending this work to immunotherapy, one could now strategically design antibodies by altering glycosylation in Fc regions or transferring the Fc region of CXCR3-173 to Fabs or single chain Fragment variables (scFvs) to induce fragmentation of tumor cells and patrolling monocytes which are known to benefit tumor growth at the expense of the host.